Efficacy Of Arsenic Trioxide Drug-eluting Stents In The Treatment Of Coronary Heart Disease

Objective:The study aim was to evaluate the safety and clinical efficacy of arsenic trioxide drug-eluting(AVI)stents,manufactured in China,in the treatment of patients with coronary heart disease(CHD).Methods: From January to August in 2014,40 patients with CHD in our hospital with implanted AVI stents alone were selected.A 1-year clinical follow-up was completed,and 1-year postoperative coronary angiography was reviewed.Major adverse cardiovascular events(MACE),recurrent angina,stent restenosis,and stent thrombosis cases were observed.MACE including cardiac death,target lesion revascularization,nonfatal myocardial infarction.Results:All 40 CHD patients completed 1-year clinical follow-up,as well as 1-year postoperative coronary angiography.The follow-up results showed that the MACE rate was 15.0%(6/40),the target lesion revascularization rate was 15.0%(6/40),there were no cases of cardiac death or nonfatal myocardial infarction,the angina recurrence rate was 32.5%(13/40),the in-stent restenosis rate was 20.0%(8/40),and the stent thrombosis rate was 0.Conclusion:The incidence of restenosis after implantation of AVI stent was higher,and the safety and clinical efficacy were worse than expected.